Business Wire

NY-IWBI

Share
IWBI Assembles Task Force on Role Buildings Can Play in Reducing Health Burden of COVID-19 and other Respiratory Infections

The International WELL Building Institute (IWBI) announced today that it is standing up a Task Force on reducing the enormous health burden from COVID-19 and other respiratory infections. Its goal is to define the critical role buildings, organizations and communities play in prevention and preparedness, resilience and recovery. The Task Force's work will take a broad approach, considering both new and recurring infectious agents that can affect large populations.

Co-chairing the Task Force are Risa Lavizzo-Mourey, M.D., MBA , former president and CEO of the Robert Wood Johnson Foundation and distinguished professor of population health and health equity at the University of Pennsylvania; Jonathan Fielding, M.D., MPH, MA, MBA , distinguished professor at UCLA in the Fielding School of Public Health and the Geffen School of Medicine and former director and health officer of the Los Angeles County Department of Public Health; Richard Carmona, M.D., MPH, FACS , who was 17th Surgeon General of the United States and is presently distinguished professor at the University of Arizona; and Joseph Allen, DSc, MPH, assistant professor and director of the Healthy Buildings program at Harvard’s T.H. Chan School of Public Health. The task force will include experts from public health, government, academia and philanthropy, as well as the architecture, design and real estate communities.

“IWBI’s work centers on providing evidence-backed solutions that advance better health and well-being in the places and spaces where we spend our lives,” said IWBI Chairman and CEO Rick Fedrizzi. “The creation of this Task Force provides a mechanism to focus on this immediate challenge and collect and apply the expertise and insight of our global community, which includes practicing physicians, environmental and behavioral scientists, leading design practitioners and innovation leaders from global corporations.”

“This task force can help us focus quickly on actionable measures we can take to more fully deliver resources needed to advance a global culture of health that includes everyone,” said Dr. Lavizzo-Mourey.

“This timely effort will mine the scientific literature to identify enhanced opportunities for the built environment to improve population health,” said Dr. Fielding.

Surgeon General Carmona commends IWBI for bringing together global public health thought leaders to focus on optimizing the built environment to prevent, respond to, mitigate and recover from “all hazards” to the United States to include coronavirus. The built environment is an essential element in physical and mental health as well as preventing disease.

“The urgency of action towards mitigating the physical, emotional and economic impacts of this virus and other respiratory infections cannot be overstated,” said Dr. Allen. “Nor can the outsized impact that can occur if we improve our buildings, as well as the policies, protocols and procurement guidelines organizations have in place, so that they work together to protect and improve the health of everyone. This pandemic is the challenge of our time and buildings will play a central role in our response, and ultimate recovery.“

“The aim of the Task Force is twofold,” said IWBI President Rachel Gutter. “First, to identify and develop a set of signature deliverables and resources, including guidelines for individuals, organizations and communities to help them better integrate actionable insights and proven strategies into how they manage both their buildings and their organizations. Second, the Task Force will assess ways in which the WELL Building Standard (WELL) itself can be further strengthened so the system, which touches more than a half-billion square feet of space across 58 countries, can best continue to support prevention and preparedness, resiliency and recovery in this critical moment and into the future.”

Gutter noted that more information about the Task Force and how individuals can raise their hands to get involved can be found here .

“WELL already reflects the massive amount of current health research and data we’ve amassed and integrated since its launch in late 2014,” she said. “But the landscape shifted at the first of the year with the global onset of this virus. We are committed to making sure we share freely everything we’ve learned with our global community and beyond. We owe it to everyone to make sure the comprehensive, evidence-based interventions that we’ve codified in WELL move us in the direction of better health and enhanced resilience for everyone, everywhere.”

About the International WELL Building Institute
The International WELL Building Institute (IWBI) is leading the global movement to transform our buildings, communities and organizations in ways that help people thrive. The WELL v2 pilot is the latest version of its popular WELL Building Standard (WELL), and the WELL Community Standard pilot is a district scale rating system that sets a new global benchmark for healthy communities. WELL is focused exclusively on the ways that buildings and communities, and everything in them, can improve our comfort, drive better choices, and generally enhance, not compromise, our health and wellness. IWBI mobilizes the wellness community through management of the WELL AP credential, the pursuit of applicable research, the development of educational resources, and advocacy for policies that promote health and wellness everywhere. IWBI is a participant of the United Nations Global Compact, the world’s largest corporate citizenship initiative, and helps companies advance the UN Sustainable Development Goals (SDGs) through the use of WELL. More information on WELL can be found here .

International WELL Building Institute, IWBI, the WELL Building Standard, WELL v2, WELL Certified, WELL AP, WELL, WELL Portfolio, The WELL Conference, the WELL Community Standard and others, and their related logos are trademarks or certification marks of International WELL Building Institute pbc in the United States and other countries.

Social Media:

https://facebook.com/wellbuildinginstitute/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release

TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver

RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release

RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c

Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 07:00:00 CET | Press release

Leading encryption provider deepens commitment to European financial sector with rigorous new supplier qualification, building on existing UK & Ireland certification. Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It p

Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 03:00:00 CET | Press release

Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f

Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform16.12.2025 02:00:00 CET | Press release

Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies per Shine-On’s instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. ShineOn’s proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review and ongoing Phase I study, making it as a first-in-class–potential HLA-G targeted exosome platfo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye